Literature DB >> 7483138

Prognostic factors for bladder cancer.

T Otto, M Goepel, K H Heider, H Rübben.   

Abstract

Cancer of the urinary bladder is the fifth most common cancer in men and the second most urological malignancy in Western society [17], with an incidence rate per year of 29.8/100,000 males. Bladder tumors are distinguished as either invasive or superficial: invasive tumors are generally associated with poor prognosis, while 20-30% of superficial carcinomas recur and progress to become invasive and metastic [26, 27]. The most common prognostic factors for classification of urothelial cancer are staging and grading, which are based on morphological criteria. In the past decade, however, other criteria have been developed as a possible prognostic aid to better disease management, such as expression of specific cell surface antigens, DNA content, chromosomal aberrations, gene rearrangements and point mutations [26, 7]. Since most tumors of the bladder are carcinomas and are associated with dedifferentiation and high metastatic capability, we investigated whether reduced expression of so-called differentiation factors in combination with increased cell motility might be correlated with tumor progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7483138     DOI: 10.1007/bf00389564

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  25 in total

1.  [Risk-oriented classification of superficial bladder cancers].

Authors:  T Otto; H Rübben
Journal:  Urologe A       Date:  1992-07       Impact factor: 0.639

2.  Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role.

Authors:  K Vleminckx; L Vakaet; M Mareel; W Fiers; F van Roy
Journal:  Cell       Date:  1991-07-12       Impact factor: 41.582

3.  E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis.

Authors:  J H Schipper; U H Frixen; J Behrens; A Unger; K Jahnke; W Birchmeier
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

4.  Autocrine motility factor-receptor in human bladder-carcinoma - gene-expression, loss of cell-contact regulation and chromosomal mapping.

Authors:  S Silletti; J Yao; J Sanford; A Mohammed; T Otto; S Wolman; A Raz
Journal:  Int J Oncol       Date:  1993-11       Impact factor: 5.650

5.  Tumor cell autocrine motility factor.

Authors:  L A Liotta; R Mandler; G Murano; D A Katz; R K Gordon; P K Chiang; E Schiffmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

6.  Identification of B16-F1 melanoma autocrine motility-like factor receptor.

Authors:  I R Nabi; H Watanabe; A Raz
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

7.  The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells.

Authors:  H Watanabe; I R Nabi; A Raz
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

8.  Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas.

Authors:  T Otto; W Birchmeier; U Schmidt; A Hinke; J Schipper; H Rübben; A Raz
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

9.  Dissociation of Madin-Darby canine kidney epithelial cells by the monoclonal antibody anti-arc-1: mechanistic aspects and identification of the antigen as a component related to uvomorulin.

Authors:  J Behrens; W Birchmeier; S L Goodman; B A Imhof
Journal:  J Cell Biol       Date:  1985-10       Impact factor: 10.539

10.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.

Authors:  K H Heider; M Hofmann; E Hors; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more
  2 in total

1.  CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors.

Authors:  N E Stavropoulos; I Filliadis; E Ioachim; M Michael; E Mermiga; K Hastazeris; U O Nseyo
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  CA 19-9 as a serum marker in urothelial carcinoma.

Authors:  Mahander Pall; Javid Iqbal; Shrawan Kumar Singh; Satya Vati Rana
Journal:  Urol Ann       Date:  2012-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.